InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 230443

Friday, 11/18/2016 8:53:49 PM

Friday, November 18, 2016 8:53:49 PM

Post# of 346050

such as myeloid-derived suppressor cells (MDSCs), were reduced by more than 40% in the combination with the PS-targeting antibody versus anti-PD-1 alone.



...Dr. Jedd Wolchok also knows this and is why he is now coming out for PS Targeting in combo to help increase responders of other drugs.

A nice graph below, depicting just days after, how MDSC's increase and remember how clever Peregrine words things, like... "MDSC's were reduced by more than 40% .."

PS Targeting

PS Targeting

http://www.nature.com/articles/srep36663/figures/1

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News